M&A Talks and AI-Driven Revenue Beats Highlight Cross-Sector MovesGlobal Report·Sep 15 at 10:12 AMDBO-1.03%SCNX+0.10%
Scienture posts revised investor presentation, will present to analysts and investorsTradingView·Sep 14 at 08:13 PMSCNX+0.10%
SCNX: Rapid revenue growth and FDA-approved launches highlight a strong specialty pharma pipelineQuartr·Sep 14 at 08:00 PMSCNX+0.10%
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 | SCNX Stock NewsStockTitan·Sep 9 at 04:55 AMSCNX+0.10%
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statementPUBT·Aug 31 at 09:08 PMSCNX+0.10%
Analyst Maintains Buy Rating and $1.50 Price Target on Scienture Amid Strong Early Commercialization for Arbli and RezenopyTip Ranks·Aug 15 at 05:15 PMSCNX+0.10%
Scienture surges 11% after-hours after Q2 revenue jumps 510% and second product launchUS Stock Market Update·Aug 14 at 08:51 PMSCNX+0.10%
Scienture jumps on Q2 revenue surge of 510% and narrowing lossesUS Stock Market Update·Aug 14 at 04:11 PMSCNX+0.10%
Scienture falls 3% in regular trading as Q2 revenue jumps 510%US Stock Market Update·Aug 14 at 02:01 PMSCNX+0.10%
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance | SCNX Stock NewsStockTitan·Aug 14 at 04:08 AMSCNX+0.10%
